carboplatin + lenvatinib + paclitaxel

This is a combination regimen consisting of three drugs: - **Carboplatin**: a platinum-based chemotherapeutic agent that induces DNA crosslinking, leading to apoptosis in rapidly dividing cells. - **Lenvatinib**: an oral small molecule inhibitor targeting multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR1–3), fibroblast growth factor receptors (FGFR1–4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT. It inhibits angiogenesis and tumor cell proliferation. - **Paclitaxel**: a microtubule-stabilizing agent that disrupts mitosis by promoting tubulin polymerization and inhibiting depolymerization. This combination has been studied primarily in advanced non-small-cell lung cancer (NSCLC) as well as being considered for gynecologic malignancies such as endometrial carcinoma. In phase 1 studies for NSCLC, the maximum tolerated dose of lenvatinib with carboplatin/paclitaxel was established at 4 mg twice daily[1][2]. The regimen demonstrated manageable tolerability and encouraging antitumor activity in early-phase trials[2].